Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition

Advances in Cancer Research

Volumn 125, Issue , 2015, Pages 1-41

  Durmus, Selvi ^a   Hendrikx, Jeroen J M A ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

ABC transporters; Brain disposition; Chemotherapeutics; Drug disposition; Oral availability

Indexed keywords

ABC TRANSPORTER; AMINO ACID; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; ELACRIDAR; HERBACEOUS AGENT; ION; LIPID; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN ABCB1 INHIBITOR; PROTEIN ABCB1A; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ANTINEOPLASTIC ACTIVITY; APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; BRAIN; BRAIN TUMOR; CANCER CHEMOTHERAPY; CAPILLARY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; INTESTINE ABSORPTION; MOLECULAR INTERACTION; MOUSE MODEL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE; TESTIS; ANIMAL; BIOAVAILABILITY; DRUG RESISTANCE; METABOLISM; MOUSE; NEOPLASMS; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTESTINAL ABSORPTION; MICE; NEOPLASMS; TAXOIDS;

EID: 84921882675     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.10.001     Document Type: Chapter

References (139)

1. Agarwal S., Hartz A.M., Elmquist W.F., Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up. Current Pharmaceutical Design 2011, 17(26):2793-2802. [pii]. http://dx.doi.org/BSP/CPD/E-Pub/000567.
2. Agarwal S., Sane R., Gallardo J.L., Ohlfest J.R., Elmquist W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. The Journal of Pharmacology and Experimental Therapeutics 2010, 334(1):147-155.
3. Agarwal S., Uchida Y., Mittapalli R.K., Sane R., Terasaki T., Elmquist W.F. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metabolism and Disposition 2012, 40(6):1164-1169. dmd.112.044719 [pii]. 10.1124/dmd.112.044719.
4. Allen J.D., Van Dort S.C., Buitelaar M., van Tellingen O., Schinkel A.H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research 2003, 63(6):1339-1344.
5. Bardelmeijer H.A., Beijnen J.H., Brouwer K.R., Rosing H., Nooijen W.J., Schellens J.H., et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clinical Cancer Research 2000, 6(11):4416-4421.
6. Bardelmeijer H.A., Ouwehand M., Beijnen J.H., Schellens J.H., van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investigational New Drugs 2004, 22(3):219-229. , 5269612 [pii]. 10.1023/B:DRUG.0000026248.45084.21.
7. Bardelmeijer H.A., Ouwehand M., Buckle T., Huisman M.T., Schellens J.H., Beijnen J.H., et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research 2002, 62(21):6158-6164.
8. Bentz J., Tran T.T., Polli J.W., Ayrton A., Ellens H. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharmaceutical Research 2005, 22(10):1667-1677. 10.1007/s11095-005-6627-z.
9. Borst P., Elferink R.O. Mammalian ABC transporters in health and disease. Annual Review of Biochemistry 2002, 71:537-592. 102301.093055 [pii]. 10.1146/annurev.biochem.71.102301.093055.
10. Borst P., Schinkel A.H. P-glycoprotein ABCB1: A major player in drug handling by mammals. The Journal of Clinical Investigation 2013, 123(10):4131-4133.
11. Bradbury M.W. The blood-brain barrier. Experimental Physiology 1993, 78(4):453-472.
12. Chalmers A.J., Lakshman M., Chan N., Bristow R.G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology 2010, 20(4):274-281. S1053-4296(10)00043-3 [pii]. 10.1016/j.semradonc.2010.06.001.
13. Choi J.S., Choi H.K., Shin S.C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. International Journal of Pharmaceutics 2004, 275(1-2):165-170. S0378517304000675 [pii]. 10.1016/j.ijpharm.2004.01.032.
14. Choi J.S., Shin S.C. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. International Journal of Pharmaceutics 2005, 292(1-2):149-156. S0378-5173(04)00726-4 [pii]. 10.1016/j.ijpharm.2004.11.031.
15. Chuan T.S., Nguyen L.N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer 2014, 134(6):1484-1494. 10.1002/ijc.28475.
16. Cooray H.C., Blackmore C.G., Maskell L., Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002, 13(16):2059-2063.
17. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences of the United States of America 1989, 86(2):695-698.
18. de Vries N.A., Beijnen J.H., Boogerd W., van Tellingen O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Review of Neurotherapeutics 2006, 6(8):1199-1209. 10.1586/14737175.6.8.1199.
19. Dietrich C.G., de Waart D.R., Ottenhoff R., Schoots I.G., Elferink R.P. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Molecular Pharmacology 2001, 59(5):974-980.
20. Dietrich C.G., Geier A., Oude Elferink R.P. ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 2003, 52(12):1788-1795.
21. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42(12):1501-1506.
22. Durmus S., Sparidans R.W., van Esch A., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast Cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP i{dotless}nhibitor rucaparib (AG-014699). Pharmaceutical Research 2014, [Epub ahead of print]. 10.1007/s11095-014-1442-z.
23. Durmus S., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Molecular Pharmaceutics 2012, 9(11):3236-3245. 10.1021/mp3003144.
24. Durmus S., Xu N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacological Research 2013, 76:9-16. S1043-6618(13)00106-0 [pii]. 10.1016/j.phrs.2013.06.009.
25. Eadie L.N., Hughes T.P., White D.L. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology and Therapeutics 2014, 95(3):294-306. clpt2013208 [pii]. 10.1038/clpt.2013.208.
26. Eckstein N., Roper L., Haas B., Potthast H., Hermes U., Unkrig C., et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: The regulatory perspective. Journal of Experimental & Clinical Cancer Research 2014, 33:15. 1756-9966-33-15 [pii]. 10.1186/1756-9966-33-15.
27. Eigentler T.K., Meier F., Garbe C. Protein kinase inhibitors in melanoma. Expert Opinion on Pharmacotherapy 2013, 14(16):2195-2201.
28. Eisenblatter T., Galla H.J. A new multidrug resistance protein at the blood-brain barrier. Biochemical and Biophysical Research Communications 2002, 293(4):1273-1278. S0006-291X(02)00376-5 [pii]. 10.1016/S0006-291X(02)00376-5.
29. Erdem L., Giovannetti E., Leon L.G., Honeywell R., Peters G.J. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Current Topics in Medicinal Chemistry 2012, 12(15):1649-1659. CTMC-EPUB-20120911-8 [pii].
30. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921. nature03445 [pii]. 10.1038/nature03445.
31. Franke R.M., Gardner E.R., Sparreboom A. Pharmacogenetics of drug transporters. Current Pharmaceutical Design 2010, 16(2):220-230.
32. Fricker G., Nobmann S., Miller D.S. Permeability of porcine blood brain barrier to somatostatin analogues. British Journal of Pharmacology 2002, 135(5):1308-1314. 10.1038/sj.bjp.0704557.
33. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nature Reviews. Drug Discovery 2010, 9(3):215-236. nrd3028 [pii]. 10.1038/nrd3028.
34. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Current Drug Delivery 2004, 1(1):27-42.
35. Gligorov J., Lotz J.P. Preclinical pharmacology of the taxanes: Implications of the differences. The Oncologist 2004, 9(Suppl 2):3-8.
36. Goldstein G.W., Betz A.L. The blood-brain barrier. Scientific American 1986, 255(3):74-83.
37. Greig N.H. Optimizing drug delivery to brain tumors. Cancer Treatment Reviews 1987, 14(1):1-28.
38. Hagenbuch B., Gao B., Meier P.J. Transport of xenobiotics across the blood-brain barrier. News in Physiological Sciences 2002, 17:231-234.
39. Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors-A review on pharmacology, metabolism and side effects. Current Drug Metabolism 2009, 10(5):470-481.
40. Hayashi H., Sugiyama Y. Bile salt export pump (BSEP/ABCB11): Trafficking and sorting disturbances. Current Molecular Pharmacology 2013, 6(2):95-103.
41. Hendrikx J.J., Lagas J.S., Rosing H., Schellens J.H., Beijnen J.H., Schinkel A.H. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer 2013, 132(10):2439-2447. 10.1002/ijc.27912.
42. Hendrikx J.J., Lagas J.S., Wagenaar E., Rosing H., Schellens J.H., Beijnen J.H., et al. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. British Journal of Cancer 2014, 110(11):2669-2676. bjc2014222 [pii]. 10.1038/bjc.2014.222.
43. Hu S., Chen Z., Franke R., Orwick S., Zhao M., Rudek M.A., et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clinical Cancer Research 2009, 15(19):6062-6069. 10.1158/1078-0432.CCR-09-0048.
44. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International Journal of Cancer 2005, 116(5):824-829. 10.1002/ijc.21013.
45. Jackson S.E., Chester J.D. Personalised cancer medicine. International Journal of Cancer 2014, [Epub ahead of print]. 10.1002/ijc.28940.
46. Jaspers J.E., Kersbergen A., Boon U., Sol W., van Deemter L., Zander S.A., et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discovery 2013, 3(1):68-81. 2159-8290.CD-12-0049 [pii]. 10.1158/2159-8290.CD-12-0049.
47. Jin J., Bi H., Hu J., Zhong G., Zhao L., Huang Z., et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharmaceutics & Drug Disposition 2010, 31(4):264-268. 10.1002/bdd.705.
48. Jonker J.W., Buitelaar M., Wagenaar E., van der Valk M.A., Scheffer G.L., Scheper R.J., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(24):15649-15654. 202607599 [pii]. 10.1073/pnas.202607599.
49. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 2000, 92(20):1651-1656.
50. Kalvass J.C., Pollack G.M. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. Pharmaceutical Research 2007, 24(2):265-276. 10.1007/s11095-006-9135-x.
51. Kamiie J., Ohtsuki S., Iwase R., Ohmine K., Katsukura Y., Yanai K., et al. Quantitative atlas of membrane transporter proteins: Development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharmaceutical Research 2008, 25(6):1469-1483. 10.1007/s11095-008-9532-4.
52. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clinical Cancer Research 2003, 9(7):2849-2855.
53. Kemper E.M., Verheij M., Boogerd W., Beijnen J.H., van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. European Journal of Cancer 2004, 40(8):1269-1274. S0959804904001625 [pii]. 10.1016/j.ejca.2004.01.024.
54. Kimura Y., Aoki J., Kohno M., Ooka H., Tsuruo T., Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemotherapy and Pharmacology 2002, 49(4):322-328. 10.1007/s00280-001-0419-x.
55. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacological Reviews 2010, 62(1):1-96. pr.109.002014 [pii]. 10.1124/pr.109.002014.
56. Klempner S.J., Bubley G. Complementary and alternative medicines in prostate cancer: From bench to bedside?. The Oncologist 2012, 17(6):830-837. 2012-0094, theoncologist.2012-0094 [pii]. 10.1634/theoncologist.
57. Kodaira H., Kusuhara H., Ushiki J., Fuse E., Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. The Journal of Pharmacology and Experimental Therapeutics 2010, 333(3):788-796. jpet.109.162321 [pii]. 10.1124/jpet.109.162321.
58. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Journal of Clinical Oncology 2002, 20(13):2943-2950.
59. Kumar Y.S., Adukondalu D., Sathish D., Vishnu Y.V., Ramesh G., Latha A.B., et al. P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions. Drug Metabolism and Drug Interactions 2010, 25(1-4):3-16. 10.1515/DMDI.2010.006.
60. Kuppens I.E., Witteveen E.O., Jewell R.C., Radema S.A., Paul E.M., Mangum S.G., et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clinical Cancer Research 2007, 13(11):3276-3285.
61. Kwak J.O., Lee S.H., Lee G.S., Kim M.S., Ahn Y.G., Lee J.H., et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. European Journal of Pharmacology 2010, 627(1-3):92-98. S0014-2999(09)01002-4 [pii]. 10.1016/j.ejphar.2009.11.008.
62. Lagas J.S., Fan L., Wagenaar E., Vlaming M.L., van Tellingen O., Beijnen J.H., et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clinical Cancer Research 2010, 16(1):130-140. 1078-0432.CCR-09-1321 [pii]. 10.1158/1078-0432.CCR-09-1321.
63. Lagas J.S., van Waterschoot R.A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Molecular Cancer Therapeutics 2010, 9(2):319-326. 1535-7163.MCT-09-0663 [pii]. 10.1158/1535-7163.MCT-09-0663.
64. Lagas J.S., van Waterschoot R.A., van Tilburg V.A., Hillebrand M.J., Lankheet N., Rosing H., et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clinical Cancer Research 2009, 15(7):2344-2351.
65. Lagas J.S., Vlaming M.L., Schinkel A.H. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: The power of combination knockout mice. Molecular Interventions 2009, 9(3):136-145. 9/3/136 [pii]. 10.1124/mi.9.3.7.
66. Lagas J.S., Vlaming M.L., van Tellingen O., Wagenaar E., Jansen R.S., Rosing H., et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clinical Cancer Research 2006, 12(20 Pt 1):6125-6132. 12/20/6125 [pii]. 10.1158/1078-0432.CCR-06-1352.
67. Lee C.K., Choi J.S. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 2010, 85(6):350-356. 000312690 [pii]. 10.1159/000312690.
68. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacological Reviews 2001, 53(4):569-596.
69. Leggas M., Adachi M., Scheffer G.L., Sun D., Wielinga P., Du G., et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Molecular and Cellular Biology 2004, 24(17):7612-7621. 10.1128/MCB.24.17.7612-7621.2004.
70. Levitzki A. Tyrosine kinase inhibitors: Views of selectivity, sensitivity, and clinical performance. Annual Review of Pharmacology and Toxicology 2013, 53:161-185.
71. Li X., Choi J.S. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. International Journal of Pharmaceutics 2007, 337(1-2):188-193. S0378-5173(07)00014-2 [pii]. 10.1016/j.ijpharm.2007.01.002.
72. Li Y., Paxton J.W. The effects of flavonoids on the ABC transporters: Consequences for the pharmacokinetics of substrate drugs. Expert Opinion on Drug Metabolism & Toxicology 2013, 9(3):267-285. 10.1517/17425255.2013.749858.
73. Lin F., de Gooijer M.C., Roig E.M., Buil L.C., Christner S.M., Beumer J.H., et al. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clinical Cancer Research 2014, 20(10):2703-2713. 1078-0432.CCR-14-0084 [pii]. 10.1158/1078-0432.CCR-14-0084.
74. Lin F., Marchetti S., Pluim D., Iusuf D., Mazzanti R., Schellens J.H., et al. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical Cancer Research 2013, 19(8):2084-2095.
75. Lockman P.R., Mittapalli R.K., Taskar K.S., Rudraraju V., Gril B., Bohn K.A., et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical Cancer Research 2010, 16(23):5664-5678. 1078-0432.CCR-10-1564 [pii]. 10.1158/1078-0432.CCR-10-1564.
76. Marchetti S., de Vries N.A., Buckle T., Bolijn M.J., van Eijndhoven M.A., Beijnen J.H., et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics 2008, 7(8):2280-2287.
77. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. The Journal of Clinical Investigation 1997, 100(10):2430-2436.
78. Miller D.S., Nobmann S.N., Gutmann H., Toeroek M., Drewe J., Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Molecular Pharmacology 2000, 58(6):1357-1367.
79. Minocha M., Khurana V., Qin B., Pal D., Mitra A.K. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. International Journal of Pharmaceutics 2012, 434(1-2):306-314.
80. Minocha M., Khurana V., Qin B., Pal D., Mitra A.K. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. International Journal of Pharmaceutics 2012, 436(1-2):127-134.
81. Misaka S., Muller F., Fromm M.F. Clinical relevance of drug efflux pumps in the gut. Current Opinion in Pharmacology 2013, 13(6):847-852. S1471-4892(13)00156-2 [pii]. 10.1016/j.coph.2013.08.010.
82. Mittapalli R.K., Vaidhyanathan S., Dudek A.Z., Elmquist W.F. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases. The Journal of Pharmacology and Experimental Therapeutics 2013, 344(3):655-664. jpet.112.201475 [pii]. 10.1124/jpet.112.201475.
83. Oostendorp R.L., Beijnen J.H., Schellens J.H. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treatment Reviews 2009, 35(2):137-147. S0305-7372(08)00287-9 [pii]. 10.1016/j.ctrv.2008.09.004.
84. Oostendorp R.L., Buckle T., Beijnen J.H., van Tellingen O., Schellens J.H. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational New Drugs 2009, 27(1):31-40. 10.1007/s10637-008-9138-z.
85. Oplustilova L., Wolanin K., Mistrik M., Korinkova G., Simkova D., Bouchal J., et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012, 11(20):3837-3850. 22026 [pii]. 10.4161/cc.22026.
86. O'Sullivan C.C., Moon D.H., Kohn E.C., Lee J.M. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Frontiers in Oncology 2014, 4:42. 10.3389/fonc.2014.00042.
87. Pander J., Guchelaar H.J., Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. Current Opinion in Molecular Therapeutics 2010, 12(6):654-661.
88. Park J.H., Park J.H., Hur H.J., Woo J.S., Lee H.J. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. European Journal of Pharmaceutical Sciences 2012, 45(3):296-301. S0928-0987(11)00428-3 [pii]. 10.1016/j.ejps.2011.11.021.
89. Peng S.X., Ritchie D.M., Cousineau M., Danser E., Dewire R., Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. Journal of Pharmaceutical Sciences 2006, 95(9):1984-1993. 10.1002/jps.20664.
90. Philippou Y., Hadjipavlou M., Khan S., Rane A. Complementary and alternative medicine (CAM) in prostate and bladder cancer. BJU International 2013, 112(8):1073-1079. 10.1111/bju.12062.
91. Pluchino K.M., Hall M.D., Goldsborough A.S., Callaghan R., Gottesman M.M. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resistance Updates 2012, 15(1-2):98-105.
92. Poller B., Iusuf D., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metabolism and Disposition 2011, 39(5):729-735. dmd.110.037317 [pii]. 10.1124/dmd.110.037317.
93. Polli J.W., Olson K.L., Chism J.P., John-Williams L.S., Yeager R.L., Woodard S.M., et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metabolism and Disposition 2009, 37(2):439-442. dmd.108.024646 [pii]. 10.1124/dmd.108.024646.
94. Potschka H., Fedrowitz M., Loscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia 2003, 44(12):1479-1486.
95. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(44):17079-17084. 0806092105 [pii]. 10.1073/pnas.0806092105.
96. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nature Reviews Cancer 2010, 10(4):293-301. nrc2812 [pii]. 10.1038/nrc2812.
97. Salphati L., Heffron T.P., Alicke B., Nishimura M., Barck K., Carano R.A., et al. Targeting the PI3K pathway in the brain-efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clinical Cancer Research 2012, 18(22):6239-6248. 1078-0432.CCR-12-0720 [pii]. 10.1158/1078-0432.CCR-12-0720.
98. Schellens J.H., Malingre M.M., Kruijtzer C.M., Bardelmeijer H.A., van Tellingen O., Schinkel A.H., et al. Modulation of oral bioavailability of anticancer drugs: From mouse to man. European Journal of Pharmaceutical Sciences 2000, 12(2):103-110. [pii]. http://dx.doi.org/S0928-0987(00)00153-6.
99. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Advanced Drug Delivery Reviews 2003, 55(1):3-29.
100. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of Clinical Investigation 1996, 97(11):2517-2524. 10.1172/JCI118699.
101. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. The Journal of Clinical Investigation 1995, 96(4):1698-1705.
102. Shibayama Y., Nakano K., Maeda H., Taguchi M., Ikeda R., Sugawara M., et al. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biological & Pharmaceutical Bulletin 2011, 34(3):433-435.
103. Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., Schinkel A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. The Journal of Clinical Investigation 1999, 104(10):1441-1447.
104. Soontornmalai A., Vlaming M.L., Fritschy J.M. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006, 138(1):159-169. 10.1016/j.neuroscience.2005.11.011.
105. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(5):2031-2035.
106. Sparreboom A., van Tellingen O., Nooijen W.J., Beijnen J.H. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs 1998, 9(1):1-17.
107. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research 2004, 64(20):7491-7499. 64/20/7491 [pii]. 10.1158/0008-5472.CAN-04-0096.
108. Stuurman F.E., Nuijen B., Beijnen J.H., Schellens J.H. Oral anticancer drugs: Mechanisms of low bioavailability and strategies for improvement. Clinical Pharmacokinetics 2013, 52(6):399-414. 10.1007/s40262-013-0040-2.
109. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. European Journal of Pharmaceutical Sciences 2000, 12(1):3-12. [pii]. http://dx.doi.org/S0928-0987(00)00178-0.
110. Szakacs G., Varadi A., Ozvegy-Laczka C., Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today 2008, 13(9-10):379-393. S1359-6446(08)00007-X [pii]. 10.1016/j.drudis.2007.12.010.
111. Tamaki A., Ierano C., Szakacs G., Robey R.W., Bates S.E. The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry 2011, 50(1):209-232.
112. Tang S.C., de Vries N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. The Journal of Pharmacology and Experimental Therapeutics 2013, 346(3):486-494. jpet.113.205583 [pii]. 10.1124/jpet.113.205583.
113. Tang S.C., Hendrikx J.J., Beijnen J.H., Schinkel A.H. Genetically modified mouse models for oral drug absorption and disposition. Current Opinion in Pharmacology 2013, 13(6):853-858. S1471-4892(13)00157-4 [pii]. 10.1016/j.coph.2013.08.011.
114. Tang S.C., Lagas J.S., Lankheet N.A., Poller B., Hillebrand M.J., Rosing H., et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer 2012, 130(1):223-233. 10.1002/ijc.26000.
115. Tang S.C., Lankheet N.A., Poller B., Wagenaar E., Beijnen J.H., Schinkel A.H. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. The Journal of Pharmacology and Experimental Therapeutics 2012, 341(1):164-173. jpet.111.186908 [pii]. 10.1124/jpet.111.186908.
116. Tang S.C., Sparidans R.W., Cheung K.L., Fukami T., Durmus S., Wagenaar E., et al. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR inhibitor everolimus (afinitor) in mice. Clinical Cancer Research 2014, 20(12):3133-3145. 1078-0432.CCR-13-1759 [pii]. 10.1158/1078-0432.CCR-13-1759.
117. Ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clinical Pharmacokinetics 2003, 42(7):665-685. 4275 [pii]. 10.2165/00003088-200342070-00005.
118. Tiwari A.K., Zhang R., Gallo J.M. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Molecular Cancer Therapeutics 2013, 12(7):1343-1355. 10.1158/1535-7163.MCT-13-0100.
119. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. Journal of Neurochemistry 2011, 117(2):333-345. 10.1111/j.1471-4159.2011.07208.x.
120. Uchida Y., Tachikawa M., Obuchi W., Hoshi Y., Tomioka Y., Ohtsuki S., et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: Application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids and Barriers of the CNS 2013, 10(1):21. 10.1186/2045-8118-10-21.
121. Vaidhyanathan S., Mittapalli R.K., Sarkaria J.N., Elmquist W.F. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: Implications for combination therapy for melanoma brain metastases. Drug Metabolism and Disposition 2014, 42(8):1292-1300.
122. van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. British Journal of Cancer 1997, 76(9):1181-1183.
123. van Asperen J., van Tellingen O., van der Valk M.A., Rozenhart M., Beijnen J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clinical Cancer Research 1998, 4(10):2293-2297.
124. van Herwaarden A.E., Schinkel A.H. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends in Pharmacological Sciences 2006, 27(1):10-16.
125. van Waterschoot R.A., Lagas J.S., Wagenaar E., Rosing H., Beijnen J.H., Schinkel A.H. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer 2010, 127(12):2959-2964. 10.1002/ijc.25279.
126. van Waterschoot R.A., Lagas J.S., Wagenaar E., van der Kruijssen C.M., van Herwaarden A.E., Song J.Y., et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Research 2009, 69(23):8996-9002. 0008-5472.CAN-09-2915 [pii]. 10.1158/0008-5472.CAN-09-2915.
127. van Waterschoot R.A., Schinkel A.H. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: Recent insights from knockout and transgenic mice. Pharmacological Reviews 2011, 63(2):390-410.
128. Vlaming M.L., Lagas J.S., Schinkel A.H. Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice. Advanced Drug Delivery Reviews 2009, 61(1):14-25. S0169-409X(08)00253-6 [pii]. 10.1016/j.addr.2008.08.007.
129. Vlaming M.L., Teunissen S.F., van de Steeg E., van Esch A., Wagenaar E., Brunsveld L., et al. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: Altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology 2014, 85(3):520-530. mol.113.088823 [pii]. 10.1124/mol.113.088823.
130. Wang T., Agarwal S., Elmquist W.F. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics 2012, 341(2):386-395. jpet.111.190488 [pii]. 10.1124/jpet.111.190488.
131. Watanabe T., Kusuhara H., Maeda K., Shitara Y., Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. The Journal of Pharmacology and Experimental Therapeutics 2009, 328(2):652-662. jpet.108.146647 [pii]. 10.1124/jpet.108.146647.
132. Wiernik P.H. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clinical Advances in Hematology & Oncology 2010, 8(6):429-436. 444.
133. Yan Y.D., Kim D.H., Sung J.H., Yong C.S., Choi H.G. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. International Journal of Pharmaceutics 2010, 399(1-2):116-120. S0378-5173(10)00620-4 [pii]. 10.1016/j.ijpharm.2010.08.015.
134. Yang J.J., Milton M.N., Yu S., Liao M., Liu N., Wu J.T., et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metabolism Letters 2010, 4(4):201-212.
135. Yang L.Q., Wang B., Gan H., Fu S.T., Zhu X.X., Wu Z.N., et al. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo. Biopharmaceutics & Drug Disposition 2012, 33(8):425-436. 10.1002/bdd.1806.
136. Zamek-Gliszczynski M.J., Bedwell D.W., Bao J.Q., Higgins J.W. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metabolism and Disposition 2012, 40(9):1825-1833. dmd.112.046508 [pii]. 10.1124/dmd.112.046508.
137. Zamek-Gliszczynski M.J., Kalvass J.C., Pollack G.M., Brouwer K.L. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metabolism and Disposition 2009, 37(2):386-390. dmd.108.023648 [pii]. 10.1124/dmd.108.023648.
138. Zhou L., Schmidt K., Nelson F.R., Zelesky V., Troutman M.D., Feng B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metabolism and Disposition 2009, 37(5):946-955. dmd.108.024489 [pii]. 10.1124/dmd.108.024489.
139. Zimmermann C., van de Wetering K., van de Steeg E., Wagenaar E., Vens C., Schinkel A.H. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metabolism and Disposition 2008, 36(4):631-640. 10.1124/dmd.107.019620.